Want to see SRZN full AI Analyst Report?
SRZN Stock Chart & Stats
$23.36
-$0.60(-3.04%)
At close: 4:00 PM EDT
$23.36
-$0.60(-3.04%)
Day’s Range― - ―
52-Week Range$11.39 - $37.83
Previous CloseN/A
Volume104.46K
Average Volume (3M)833.48K
Market Cap
$279.15M
Enterprise Value$504.92M
Total Cash (Recent Filing)$102.04M
Total Debt (Recent Filing)$6.32M
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
Nov 11, 2026EPS Estimate
-1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.13
Shares Outstanding11,753,558
10 Day Avg. Volume801,977
30 Day Avg. Volume833,483
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.90
Price to Sales (P/S)48.61
P/FCF Ratio-5.56
Enterprise Value/Market Cap1.81
Enterprise Value/Revenue43.86
Enterprise Value/Gross Profit44.11
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$47.50Price Target Upside103.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-6.81
Revenue Forecast (FY)$10.75M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe revenue rebound indicates renewed activity in the company’s funding or collaboration-related business after a weak 2025. Although Surrozen remains pre-commercial, stronger reported revenue can provide incremental support for research execution and improve the platform’s financial trajectory if sustained.
FDA-Cleared PipelineFDA clearance removes a key regulatory barrier for SZN-8141 and allows Surrozen to advance into clinical testing for diabetic macular edema. Progress into human studies, with additional retinal indications planned, broadens the development pipeline and creates longer-term value-creation opportunities.
Development FundingExpected financing proceeds would materially improve near-term funding visibility for SZN-8141, SZN-8143, and broader operations. Greater access to capital can extend development capacity and reduce immediate liquidity pressure, although the proceeds remain subject to closing conditions and involve issued securities.
Bears Say
Severe UnprofitabilityThe scale of the net loss relative to $11.5M of TTM revenue shows that operating expenses remain far above the company’s current revenue base. Without substantial clinical or commercial scale, this cost structure can continue to pressure capital needs and limit financial resilience.
Negative EquityPersistently negative equity reflects a sharp deterioration in balance-sheet quality and leaves Surrozen with reduced financial flexibility. Even though absolute debt is modest, the deficit increases dependence on future financings and raises the risk that additional capital could dilute existing shareholders.
Ongoing Cash BurnContinued negative operating and free cash flow indicates that Surrozen is not self-funding its research and development activities. The business therefore remains dependent on external capital, making liquidity management and financing access important constraints over the next several quarters.
Surrozen News
SRZN FAQ
What was Surrozen’s price range in the past 12 months?
Surrozen lowest stock price was $11.39 and its highest was $37.83 in the past 12 months.
What is Surrozen’s market cap?
Surrozen’s market cap is $279.15M.
When is Surrozen’s upcoming earnings report date?
Surrozen’s upcoming earnings report date is Nov 11, 2026 which is in 26 days.
How were Surrozen’s earnings last quarter?
Surrozen released its earnings results on Aug 06, 2026. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$1.288 by $0.878.
Is Surrozen overvalued?
According to Wall Street analysts Surrozen’s price is currently Undervalued.
Does Surrozen pay dividends?
Surrozen does not currently pay dividends.
What is Surrozen’s EPS estimate?
Surrozen’s EPS estimate is -1.1.
How many shares outstanding does Surrozen have?
Surrozen has 11,753,558 shares outstanding.
What happened to Surrozen’s price movement after its last earnings report?
Surrozen reported an EPS of -$0.41 in its last earnings report, beating expectations of -$1.288. Following the earnings report the stock price went up 18.392%.
Which hedge fund is a major shareholder of Surrozen?
Currently, no hedge funds are holding shares in SRZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Surrozen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.50 (103.34% Upside)
$47.50 (103.34% Upside)
Blogger Sentiment
Neutral
SRZN Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 56.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.32%
12-Months-Change
Fundamentals
Return on Equity
187.62%
Trailing 12-Months
Asset Growth
12.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Surrozen
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
SRZN Stock 12 Month Forecast
Average Price Target
$47.50
▲(103.34% Upside)
Technical Analysis
Opus Genetics
―
Ovid Therapeutics
―
Shattuck Labs
―
Spruce Biosciences
―
Biomea Fusion
―
Ownership Overview
43.85% Insiders
1.87% Mutual Funds
5.73% Other Institutional Investors
42.35% Public Companies and
Individual Investors